Pivotal trial evaluated the safety and efficacy of the Hēlo ™ Thrombectomy System for the removal of blood clots from the lungs

MENLO PARK, Calif. , Nov. 3, 2025 /PRNewswire/ -- Dr. Andrew Klein, ENGULF National Co-Principal Investigator at Piedmont Hospital in Atlanta, today presented the positive results of the pivotal cohort of the ENGULF Investigational Device Exemption (IDE) study as a late-breaking clinical trial at the annual VIVA conference in Las Vegas. The data supports the technological advancements of the Hēlo ™ Thrombectomy System, a novel technology designed for the treatment of pulmonary embolism (PE)—a life-threatening condition caused by blood clots in the lungs. The Hēlo Thrombectomy System represents a breakthrough in clot removal technology, featuring a unique c

See Full Page